CLDI

23.85% -0.238

시장 영업 전: .73 -0.03 -3.95%

Calidi Biotherapeutics Inc (CLDI)

개요 뉴스 가격 이력 토론 예측

Relative Volume:

Calidi Biotherapeutics Inc Stock (CLDI) Company Profile

Calidi Biotherapeutics Inc

Healthcare (1164)

Biotechnology (655)

(858) 794-9600

4475 Executive Drive, Suite 200, San Diego

최신 SEC 제출 서류

CLDI's Discussions on Twitter

CLDI을(를) 다른 주식과 비교

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
CLDI Calidi Biotherapeutics Inc	0.76	10.93M	0	-23.36M	0	-0.7368
VRTX Vertex Pharmaceuticals Inc	468.85	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	567.74	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	314.94	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	560.24	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	250.30	28.51B	3.81B	-644.79M	-669.77M	-6.24

Calidi Biotherapeutics Inc Stock (CLDI) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2023-11-22	개시	H.C. Wainwright	Buy
2023-10-09	개시	Robert W. Baird	Outperform

Calidi Biotherapeutics Inc 주식(CLDI)의 최신 뉴스

Calidi Biotherapeutics Inc (CLDI) 재무 분석

Calidi Biotherapeutics Inc (CLDI)

Calidi Biotherapeutics Inc Stock (CLDI) Company Profile

CLDI을(를) 다른 주식과 비교

Calidi Biotherapeutics Inc Stock (CLDI) Upgrades & Downgrades

Calidi Biotherapeutics Inc 주식(CLDI)의 최신 뉴스

Calidi Biotherapeutics Approves Key Proposals at Annual Meeting - TipRanks

Top Penny Stocks To Add to Your Watchlist – July 9th - Defense World

Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up - Quantisnow

Calidi Biotherapeutics: Redefining Cancer Treatment with Breakthrough Virotherapy - AInvest

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Platform Designed to Transform Landscape of Cancer Treatment - The Manila Times

Breakthrough Cancer Treatment: Calidi's New Genetic Platform Targets Both Primary and Metastatic Tumors - Stock Titan

Calidi Biotherapeutics Cashes In On Warrant Agreement - Finimize

Calidi Biotherapeutics secures $4.6 million through warrant exercise By Investing.com - Investing.com Nigeria

Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds - GlobeNewswire

Clinical-Stage Biotech Calidi Raises $4.6M in Fresh Capital: Accelerates Targeted Therapy Programs - Stock Titan

Crude Oil Moves Higher; RxSight Shares Plunge - Benzinga

Dow Jumps 200 Points; US Wholesale Inventories Fall 0.3% In May - Benzinga

Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers - FinancialContent

Calidi Biotherapeutics Stock Soars 174.93% on Precision Medicine Hype - AInvest

Calidi Biotherapeutics Soars 119.7% on Cancer Trial News - AInvest

Calidi Biotherapeutics Stock Jumps 39% After Hours — What's Going On - Benzinga

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Developing Precision Genetic Medicine Platform for Cancer Treatment - Yahoo Finance

Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs – Company AnnouncementFT.com - Financial Times

Calidi Biotherapeutics (CLDI): A Breakthrough in Systemic Virotherapy and the $564B Oncology Opportunity - AInvest

Calidi Biotherapeutics (NYSE:CLDI) Shares Up 5.6% – Still a Buy? - Defense World

CLDI SEC FilingsCalidi Biotherapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Calidi Biotherapeutics Granted Patent for Cell-Based Oncolytic Virus Immunotherapy for Cancer Treatment - ACCESS Newswire

Certain Warrants of Calidi Biotherapeutics, Inc. are subject to a Lock-Up Agreement Ending on 30-JUN-2025. - MarketScreener

Calidi Bio's Revolutionary Cancer Platform RedTail Races to Clinical Trials: CEO Reveals 2026 Timeline - Stock Titan

Millennium Management LLC Increases Stake in Calidi Biotherapeutics, Inc. (NYSE:CLDI) - Defense World

Calidi Biotherapeutics Appoints Biotech Veteran Eric Poma, PhD, as CEO to Lead Next Growth Phase - citybuzz -

Jane Street Group LLC Takes Position in Calidi Biotherapeutics, Inc. (NYSE:CLDI) - Defense World

Calidi Biotherapeutics Unveils Promising Data on CLD-401 at ASCO 2025 - citybuzz -

Calidi Biotherapeutics Presents systemic oncolytic platform - GlobeNewswire

Calidi Biotherapeutics (CLDI) Showcases Innovative CLD-401 Thera - GuruFocus

Revolutionary Cancer Treatment Breakthrough: Calidi's New Systemic Delivery Platform Wows ASCO Conference - Stock Titan

Calidi Biotherapeutics Presents systemic oncolytic platform with CD55-Enhanced expression and IL-15 Superagonist Payload at ASCO Annual Meeting - The Manila Times

Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock - The Globe and Mail

Calidi Biotherapeutics (NYSE:CLDI) Shares Down 5.3% – Time to Sell? - Defense World

Calidi Biotherapeutics, Inc. (CLDI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Yahoo Finance

Calidi Biotherapeutics Reports First Quarter 2025 Financial Results And Recent Operational Highlights - marketscreener.com

Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights - GlobeNewswire

Calidi Biotherapeutics Secures FDA Green Light for Cancer Trial as New CEO Reveals Q1 Financials - Stock Titan

Candel Therapeutics (NASDAQ:CADL) vs. Calidi Biotherapeutics (NYSE:CLDI) Critical Review - Defense World

Geode Capital Management LLC Buys 120,406 Shares of Calidi Biotherapeutics, Inc. (NYSE:CLDI) - Defense World

CLDICalidi Biotherapeutics Inc Latest Stock News & Market Updates - Stock Titan

Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on February 5 - The Globe and Mail

Calidi Biotherapeutics (NYSE:CLDI) Stock Price Down 0.3% – Time to Sell? - Defense World

Investor’s Delight: Calidi Biotherapeutics Inc (CLDI) Closes Weak at 0.65, Down -6.53 - DWinneX

Calidi (CLDI) Advances Cancer Treatment with IL15 Superagonist a - GuruFocus

Calidi Biotherapeutics Announces IL15 Superagonist as First - GlobeNewswire

Revolutionary Cancer Treatment Platform Shows Complete Tumor Elimination: First Systemic Delivery Success - Stock Titan

Calidi Biotherapeutics (CLDI) Awards Stock Option to New CEO Eri - GuruFocus

Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 - The Manila Times

Calidi Bio's Strategic Move: New CEO Secures 726K Share Options with 4-Year Performance Lock - Stock Titan

Calidi Biotherapeutics appoints new CEO By Investing.com - Investing.com South Africa

Calidi Biotherapeutics Inc (CLDI) 재무 분석

매출

순이익

현금흐름

주당 순 이익

CLDI과 유사한 종목